MYC and cancer: The ability of the DEABM to effectively recapitulate the development and progression to malignancy corresponding to known genetic abnormalities associated with tumorigenesis was initially evaluated in simulations in which, a single copy of either TP53 or Myc was “mutated” within the DEABM and experimental simulations (n-individual simulations per group = 500; N-groups = 3) were conducted to determine alterations in the frequency of the occurrence of invasive cancer.